JAK1 and prostate cancer: By contrast, the expression of JAK1 was significantly decreased in bladder carcinoma, breast carcinoma, colon adenocarcinoma, chromophobe renal cell carcinoma, liver hepatocellular carcinoma, LUAD, lung squamous cell carcinoma, prostate cancer, and adenocarcinoma of the rectum (Figure 1B).